Trial · NCT00849667
Results by group81
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 81
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | 1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin | 9.5 | 95% Confidence Interval 8.6 to 10.2 | months | |
| Progression-free Survival (PFS) | 2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin | 9.7 | 95% Confidence Interval 8.8 to 10.4 | months | |
| Progression-free Survival (PFS) | Placebo Plus Taxane and Carboplatin | 9.0 | 95% Confidence Interval 8.4 to 9.8 | months | |
| Overall Survival (OS) | 1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin | 28.7 | 95% Confidence Interval 26.6 to 33.5 | months | |
| Overall Survival (OS) | 2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin | 32.1 | 95% Confidence Interval 26.7 to 35.0 | months | |
| Overall Survival (OS) | Placebo Plus Taxane and Carboplatin | 29.1 | 95% Confidence Interval 25.6 to 30.7 | months | |
| Cancer Antigen-125 (CA-125) Progression-Free Survival | 1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin | 13.2 | 95% Confidence Interval 11.8 to 14.4 | months | |
| Cancer Antigen-125 (CA-125) Progression-Free Survival | 2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin | 18.1 | 95% Confidence Interval 12.7 to NA | months | |
| Cancer Antigen-125 (CA-125) Progression-Free Survival | Placebo Plus Taxane and Carboplatin | 12.0 | 95% Confidence Interval 11.1 to 14.6 | months | |
| Progression-Free Survival Based on Gynecologic Cancer InterGroup (GCIG) Criteria | 1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin | 8.8 | 95% Confidence Interval 8.4 to 9.7 | months | |
| Progression-Free Survival Based on Gynecologic Cancer InterGroup (GCIG) Criteria | 2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin | 8.6 | 95% Confidence Interval 8.3 to 9.5 | months | |
| Progression-Free Survival Based on Gynecologic Cancer InterGroup (GCIG) Criteria | Placebo Plus Taxane and Carboplatin | 8.4 | 95% Confidence Interval 8.2 to 9.0 | months | |
| Percentage of Participants With Length of Second Remission Greater Than First Remission | 1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin | 4.0 | 95% Confidence Interval 1.8 to 7.8 | percentage of participants | |
| Percentage of Participants With Length of Second Remission Greater Than First Remission | 2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin | 6.5 | 95% Confidence Interval 3.5 to 10.9 | percentage of participants | |
| Percentage of Participants With Length of Second Remission Greater Than First Remission | Placebo Plus Taxane and Carboplatin | 4.5 | 95% Confidence Interval 2.1 to 8.3 | percentage of participants | |
| Percentage of Participants With Objective Response | 1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin | 57.6 | 95% Confidence Interval 52.4 to 62.7 | percentage of participants | |
| Percentage of Participants With Objective Response | 2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin | 58.2 | 95% Confidence Interval 53.0 to 63.3 | percentage of participants | |
| Percentage of Participants With Objective Response | Placebo Plus Taxane and Carboplatin | 55.8 | 95% Confidence Interval 50.5 to 60.9 | percentage of participants | |
| Duration of Tumor Response | 1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin | 8.0 | 95% Confidence Interval 7.6 to 9.2 | months | |
| Duration of Tumor Response | 2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin | 8.9 | 95% Confidence Interval 7.7 to 9.7 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00849667/results